Summit Therapeutics Inc. - 8-K Filing
Summit Therapeutics partner Akeso announced updated data from the HARMONi-2 trial showing ivonescimab reduced risk of death by 27% compared to pembrolizumab in PD-L1-positive advanced NSCLC.
Tickers: $SMMT
More Regulatory news
- LiveOne, Inc. - 8-K Filing
- Solana Co - 10-Q Filing
- Solana Co - 8-K Filing
- DeFi Development Corp. - 8-K Filing
- Stablecoin Development Corp - 8-K Filing
- BCP Investment Corp - 8-K Filing
- OneWater Marine Inc. - 8-K Filing
- Moleculin Biotech, Inc. - 8-K Filing
- Investcorp Credit Management BDC, Inc. - 8-K Filing
- Presurance Holdings, Inc. - 10-Q Filing